Patents by Inventor Shinya UMEZAKI

Shinya UMEZAKI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200352964
    Abstract: An ophthalmic aqueous composition comprises levofloxacin, a salt thereof, or a solvate thereof; dexamethasone, an ester thereof, or a salt thereof; and one or at least two isotonic agents. The ophthalmic aqueous composition is substantially free of sodium chloride. This ophthalmic aqueous composition is excellent in drug stability and drug migration and has a clear appearance.
    Type: Application
    Filed: July 24, 2020
    Publication date: November 12, 2020
    Applicants: SANTEN PHARMACEUTICAL CO., LTD., DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Yoko ENDO, Kyohei TAKAHASHI, Shinya UMEZAKI
  • Patent number: 10758554
    Abstract: An ophthalmic aqueous composition comprises levofloxacin, a salt thereof, or a solvate thereof; dexamethasone, an ester thereof, or a salt thereof; and one or at least two isotonic agents. The ophthalmic aqueous composition is substantially free of sodium chloride. This ophthalmic aqueous composition is excellent in drug stability and drug migration and has a clear appearance.
    Type: Grant
    Filed: November 5, 2015
    Date of Patent: September 1, 2020
    Assignees: SANTEN PHARMACEUTICAL CO., LTD., DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Yoko Endo, Kyohei Takahashi, Shinya Umezaki
  • Publication number: 20200147222
    Abstract: The present invention addresses the problem of providing a novel application of meglumine or a salt thereof. The present invention is an antiseptic agent consisting of meglumine or a salt thereof, and a pharmaceutical composition comprising the antiseptic agent according to the present invention, and pertaining to: a pharmaceutical composition which does not comprise benzalkonium chloride and which is placed in a reusable container; a product that comprises the pharmaceutical composition comprising the antiseptic agent according to the present invention and a reusable container; and a method of improving the antiseptic effect of the pharmaceutical composition by comprising meglumine or a salt thereof in the pharmaceutical composition that has been placed in the reusable container.
    Type: Application
    Filed: March 13, 2017
    Publication date: May 14, 2020
    Applicant: Santen Pharmaceutical Co., Ltd.
    Inventors: Toyomi Fujisawa, Koji Sakanaka, Shinya Umezaki
  • Publication number: 20190038598
    Abstract: A pharmaceutical composition includes dorzolamide or a salt thereof and brimonidine or a salt thereof and has a pH of 6.0 or more. The pharmaceutical composition preferably does not include a preservative or includes a prescribed amount thereof, wherein said prescribed amount is preferably such that the common logarithmic value of the ratio (B/A) of the number (B) of bacteria at the time of inoculation to the number (A) of bacteria when the number of viable bacteria is measured after inoculating bacteria in a test sample that consists of the preservative and water and mixing homogeneously such that the concentration of Escherichia Coli ATCC 8739 in the bacterial suspension is within the range of 105-106 cfu/mL, and collecting 1 mL of the test sample using a micropipette after the test sample has been stored for seven days at 20-25° C. while shielded from light, is 2.0 or less.
    Type: Application
    Filed: February 21, 2017
    Publication date: February 7, 2019
    Applicant: Santen Pharmaceutical Co., Ltd.
    Inventor: Shinya UMEZAKI
  • Publication number: 20170340644
    Abstract: An ophthalmic aqueous composition comprises levofloxacin, a salt thereof, or a solvate thereof; dexamethasone, an ester thereof, or a salt thereof; and one or at least two isotonic agents. The ophthalmic aqueous composition is substantially free of sodium chloride. This ophthalmic aqueous composition is excellent in drug stability and drug migration and has a clear appearance.
    Type: Application
    Filed: November 5, 2015
    Publication date: November 30, 2017
    Applicants: SANTEN PHARMACEUTICAL CO., LTD., DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Yoko ENDO, Kyohei TAKAHASHI, Shinya UMEZAKI